Overview

Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+

Status:
Unknown status
Trial end date:
2020-05-11
Target enrollment:
Participant gender:
Summary
Primary Objective: To determine the 2-year distant failure rate of maintenance tegafur-uracil in patients with squamous cell carcinoma of oral cavity with extracapsular spreading of lymph nodes. Secondary Objectives: - To determine the 2-year locoregional failure rate. - To evaluate the 2-year overall survival (OS) rate. - To evaluate the 2-year progression-free survival (PFS) rate. - To assess the safety profiles.
Phase:
Phase 2
Details
Lead Sponsor:
Chang Gung Memorial Hospital
Treatments:
Tegafur